BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations at the GBA1 Meeting 2025

  June 2, 2025

   · 

  2 min read
• Press Releases

  ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

  June 2, 2025

   · 

  15 min read
• Press Releases

  Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

  June 2, 2025

   · 

  7 min read
• Press Releases

  Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

  June 2, 2025

   · 

  3 min read
• Press Releases

  UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

  June 2, 2025

   · 

  9 min read
• Press Releases

  New Headache Medicine Research Impacting Treatment, Prevention and Quality of Life to be Presented at the American Headache Society® 67th Annual Scientific Meeting in Minneapolis, MN

  June 2, 2025

   · 

  2 min read
• Press Releases

  MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease

  June 2, 2025

   · 

  8 min read
• Press Releases

  ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody ‘IMC-002' at ASCO 2025

  June 2, 2025

   · 

  3 min read
• Press Releases

  Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

  June 2, 2025

   · 

  5 min read
• Press Releases

  Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

  June 2, 2025

   · 

  9 min read